Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
C-Reactive Protein | 135 | 2023 | 3778 | 4.990 |
Why?
|
Editorial Policies | 17 | 2018 | 451 | 4.850 |
Why?
|
Clinical Laboratory Techniques | 17 | 2017 | 738 | 3.260 |
Why?
|
Chemistry, Clinical | 11 | 2018 | 63 | 2.830 |
Why?
|
Specimen Handling | 10 | 2013 | 694 | 2.440 |
Why?
|
Disclosure | 10 | 2015 | 737 | 2.080 |
Why?
|
Clinical Medicine | 5 | 2012 | 147 | 1.840 |
Why?
|
Cholesterol, LDL | 42 | 2023 | 2354 | 1.740 |
Why?
|
Immunoassay | 28 | 2015 | 751 | 1.700 |
Why?
|
Interleukin-6 | 42 | 2023 | 3208 | 1.460 |
Why?
|
Publishing | 6 | 2018 | 833 | 1.390 |
Why?
|
Coronary Disease | 43 | 2011 | 6078 | 1.370 |
Why?
|
Periodicals as Topic | 11 | 2012 | 1429 | 1.350 |
Why?
|
Cholesterol | 36 | 2023 | 2922 | 1.200 |
Why?
|
Journalism, Medical | 3 | 2012 | 73 | 1.150 |
Why?
|
Cholesterol, HDL | 35 | 2020 | 1813 | 1.140 |
Why?
|
Lipoproteins | 23 | 2020 | 881 | 1.110 |
Why?
|
Lipids | 36 | 2016 | 3307 | 1.100 |
Why?
|
Lipoprotein(a) | 18 | 2023 | 435 | 1.040 |
Why?
|
Art | 2 | 2016 | 65 | 1.040 |
Why?
|
Gonadal Steroid Hormones | 16 | 2016 | 710 | 1.000 |
Why?
|
Apolipoproteins | 19 | 2008 | 317 | 0.990 |
Why?
|
Reagent Kits, Diagnostic | 14 | 2015 | 224 | 0.980 |
Why?
|
Biomedical Research | 10 | 2018 | 3308 | 0.980 |
Why?
|
Cardiovascular Diseases | 67 | 2023 | 15142 | 0.960 |
Why?
|
Arteriosclerosis | 15 | 2004 | 1092 | 0.920 |
Why?
|
Homocysteine | 15 | 2022 | 647 | 0.880 |
Why?
|
Conflict of Interest | 4 | 2011 | 544 | 0.870 |
Why?
|
Blood Chemical Analysis | 4 | 2016 | 440 | 0.840 |
Why?
|
Peer Review | 3 | 2019 | 209 | 0.810 |
Why?
|
Hyperlipidemias | 13 | 2020 | 789 | 0.790 |
Why?
|
Learning | 2 | 2023 | 1710 | 0.780 |
Why?
|
Inflammation | 47 | 2020 | 10629 | 0.780 |
Why?
|
Research Support as Topic | 5 | 2011 | 705 | 0.750 |
Why?
|
Fasting | 24 | 2016 | 1590 | 0.740 |
Why?
|
Clinical Chemistry Tests | 5 | 2008 | 61 | 0.730 |
Why?
|
Heptanoic Acids | 12 | 2012 | 343 | 0.720 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2023 | 3255 | 0.700 |
Why?
|
Reference Values | 31 | 2016 | 4974 | 0.700 |
Why?
|
Nephelometry and Turbidimetry | 20 | 2007 | 91 | 0.690 |
Why?
|
Troponin I | 13 | 2012 | 619 | 0.670 |
Why?
|
Industry | 5 | 2011 | 366 | 0.650 |
Why?
|
Laboratories | 6 | 2023 | 462 | 0.630 |
Why?
|
Chromatography, High Pressure Liquid | 14 | 2005 | 1574 | 0.630 |
Why?
|
Sex Hormone-Binding Globulin | 17 | 2016 | 546 | 0.630 |
Why?
|
Humans | 454 | 2023 | 743811 | 0.630 |
Why?
|
Education, Professional | 1 | 2018 | 54 | 0.620 |
Why?
|
Serum Amyloid A Protein | 17 | 2013 | 121 | 0.620 |
Why?
|
Intercellular Adhesion Molecule-1 | 21 | 2011 | 1159 | 0.610 |
Why?
|
Adiponectin | 15 | 2023 | 1101 | 0.590 |
Why?
|
Pravastatin | 12 | 2012 | 395 | 0.580 |
Why?
|
Diagnostic Tests, Routine | 5 | 2021 | 782 | 0.570 |
Why?
|
Apolipoproteins B | 15 | 2020 | 374 | 0.570 |
Why?
|
Peripheral Vascular Diseases | 9 | 2008 | 549 | 0.560 |
Why?
|
Leptin | 12 | 2023 | 1600 | 0.550 |
Why?
|
Medicine | 2 | 2023 | 945 | 0.550 |
Why?
|
Drug Industry | 3 | 2010 | 746 | 0.550 |
Why?
|
Troponin T | 15 | 2012 | 754 | 0.550 |
Why?
|
Triglycerides | 29 | 2016 | 2453 | 0.540 |
Why?
|
Hypercholesterolemia | 12 | 2015 | 1151 | 0.520 |
Why?
|
Pyrroles | 12 | 2012 | 1147 | 0.520 |
Why?
|
Testosterone | 16 | 2014 | 2297 | 0.520 |
Why?
|
Acute Coronary Syndrome | 13 | 2023 | 2337 | 0.520 |
Why?
|
Portraits as Topic | 1 | 2015 | 33 | 0.520 |
Why?
|
Myocardial Infarction | 42 | 2023 | 11708 | 0.510 |
Why?
|
Lead Poisoning | 5 | 2013 | 301 | 0.500 |
Why?
|
Estradiol | 14 | 2014 | 2017 | 0.500 |
Why?
|
Angina, Unstable | 13 | 2008 | 926 | 0.490 |
Why?
|
C-Peptide | 11 | 2015 | 420 | 0.490 |
Why?
|
Middle Aged | 238 | 2019 | 213241 | 0.460 |
Why?
|
Troponin | 11 | 2010 | 524 | 0.460 |
Why?
|
Photography | 1 | 2016 | 519 | 0.450 |
Why?
|
Case-Control Studies | 68 | 2023 | 21733 | 0.450 |
Why?
|
Risk Factors | 130 | 2023 | 72252 | 0.450 |
Why?
|
Fetal Blood | 7 | 2012 | 1318 | 0.440 |
Why?
|
Diabetes Mellitus, Type 2 | 34 | 2013 | 11729 | 0.430 |
Why?
|
Diabetic Angiopathies | 10 | 2009 | 819 | 0.430 |
Why?
|
Schools, Medical | 1 | 2019 | 879 | 0.420 |
Why?
|
Ultracentrifugation | 7 | 2004 | 182 | 0.420 |
Why?
|
Fibrinogen | 10 | 2023 | 894 | 0.400 |
Why?
|
Information Services | 1 | 2012 | 244 | 0.390 |
Why?
|
Publication Bias | 2 | 2010 | 162 | 0.390 |
Why?
|
Dextran Sulfate | 5 | 2000 | 236 | 0.390 |
Why?
|
Anticholesteremic Agents | 12 | 2011 | 979 | 0.390 |
Why?
|
Busulfan | 2 | 2005 | 263 | 0.390 |
Why?
|
Female | 252 | 2023 | 380020 | 0.380 |
Why?
|
Pancreatic Neoplasms | 9 | 2023 | 5264 | 0.380 |
Why?
|
Chemistry | 1 | 2010 | 352 | 0.380 |
Why?
|
Atherosclerosis | 9 | 2023 | 3445 | 0.370 |
Why?
|
Sensitivity and Specificity | 33 | 2015 | 14714 | 0.370 |
Why?
|
Teaching | 1 | 2018 | 1173 | 0.370 |
Why?
|
Male | 229 | 2023 | 349776 | 0.370 |
Why?
|
Research Design | 8 | 2021 | 5983 | 0.370 |
Why?
|
Mass Spectrometry | 4 | 2014 | 2203 | 0.370 |
Why?
|
Blood Proteins | 3 | 2013 | 1125 | 0.370 |
Why?
|
Diagnosis | 3 | 2017 | 154 | 0.370 |
Why?
|
Research Report | 2 | 2021 | 355 | 0.370 |
Why?
|
Natriuretic Peptide, Brain | 10 | 2013 | 1572 | 0.360 |
Why?
|
Postmenopause | 17 | 2013 | 2458 | 0.360 |
Why?
|
Prospective Studies | 90 | 2023 | 53250 | 0.360 |
Why?
|
Science | 1 | 2012 | 239 | 0.360 |
Why?
|
Antibodies, Heterophile | 2 | 2008 | 126 | 0.350 |
Why?
|
Fibrin Fibrinogen Degradation Products | 9 | 2009 | 426 | 0.350 |
Why?
|
Peer Review, Research | 1 | 2013 | 329 | 0.350 |
Why?
|
Albuminuria | 9 | 2015 | 681 | 0.340 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 14 | 2013 | 707 | 0.340 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 11 | 2016 | 357 | 0.340 |
Why?
|
Financing, Organized | 1 | 2010 | 202 | 0.340 |
Why?
|
Macular Degeneration | 3 | 2007 | 981 | 0.330 |
Why?
|
Reference Standards | 12 | 2015 | 1023 | 0.330 |
Why?
|
Chromatography, Gas | 5 | 1998 | 156 | 0.330 |
Why?
|
Lead | 4 | 2013 | 852 | 0.330 |
Why?
|
Adult | 152 | 2023 | 213889 | 0.320 |
Why?
|
Scientific Misconduct | 3 | 2018 | 71 | 0.320 |
Why?
|
Academies and Institutes | 1 | 2011 | 317 | 0.320 |
Why?
|
Autoanalysis | 7 | 2003 | 72 | 0.320 |
Why?
|
Students | 1 | 2018 | 1647 | 0.320 |
Why?
|
Receptors, Leptin | 5 | 2023 | 361 | 0.320 |
Why?
|
Goiter | 1 | 2008 | 87 | 0.310 |
Why?
|
Regression Analysis | 19 | 2008 | 6457 | 0.310 |
Why?
|
Angina Pectoris | 6 | 2007 | 977 | 0.310 |
Why?
|
Risk | 32 | 2015 | 9677 | 0.310 |
Why?
|
Inflammation Mediators | 8 | 2013 | 1888 | 0.300 |
Why?
|
Amides | 5 | 2013 | 459 | 0.300 |
Why?
|
Physical Endurance | 4 | 1999 | 370 | 0.300 |
Why?
|
Aged | 136 | 2018 | 163178 | 0.300 |
Why?
|
Drug Monitoring | 7 | 2005 | 953 | 0.290 |
Why?
|
Predictive Value of Tests | 34 | 2013 | 15067 | 0.290 |
Why?
|
Insulin-Like Growth Factor I | 7 | 2014 | 2017 | 0.290 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2010 | 781 | 0.280 |
Why?
|
Risk Assessment | 36 | 2013 | 23327 | 0.280 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 15 | 2012 | 3874 | 0.280 |
Why?
|
Magnesium | 3 | 2000 | 813 | 0.280 |
Why?
|
Peptide Mapping | 1 | 2006 | 263 | 0.280 |
Why?
|
Endothelium, Vascular | 12 | 2015 | 4459 | 0.270 |
Why?
|
Thyrotropin | 2 | 2008 | 850 | 0.270 |
Why?
|
Research | 4 | 2014 | 1999 | 0.270 |
Why?
|
Heart Diseases | 6 | 2006 | 2789 | 0.260 |
Why?
|
Blood Pressure | 17 | 2010 | 8551 | 0.260 |
Why?
|
Thrombolytic Therapy | 8 | 2010 | 2162 | 0.260 |
Why?
|
Adipokines | 3 | 2023 | 320 | 0.260 |
Why?
|
Clinical Trials as Topic | 6 | 2014 | 7908 | 0.260 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 3 | 2014 | 424 | 0.260 |
Why?
|
Lipoproteins, HDL | 6 | 2009 | 640 | 0.260 |
Why?
|
Double-Blind Method | 24 | 2023 | 12020 | 0.260 |
Why?
|
Myoglobin | 7 | 2008 | 160 | 0.250 |
Why?
|
Terminology as Topic | 3 | 2015 | 1546 | 0.250 |
Why?
|
Chemistry Techniques, Analytical | 1 | 2005 | 49 | 0.250 |
Why?
|
Lipid Peroxidation | 4 | 2007 | 270 | 0.250 |
Why?
|
Program Development | 1 | 2011 | 1314 | 0.250 |
Why?
|
Adiposity | 6 | 2016 | 1806 | 0.250 |
Why?
|
Hypertriglyceridemia | 4 | 2022 | 295 | 0.250 |
Why?
|
Protein Array Analysis | 1 | 2006 | 411 | 0.240 |
Why?
|
Iron | 8 | 2008 | 1774 | 0.240 |
Why?
|
Cell Adhesion Molecules | 7 | 2015 | 1602 | 0.240 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 277 | 0.240 |
Why?
|
Bibliometrics | 1 | 2008 | 338 | 0.240 |
Why?
|
Registries | 3 | 2017 | 8090 | 0.240 |
Why?
|
Cotinine | 1 | 2004 | 206 | 0.240 |
Why?
|
Entrepreneurship | 2 | 2015 | 24 | 0.240 |
Why?
|
Obesity | 21 | 2016 | 12744 | 0.230 |
Why?
|
Apolipoproteins A | 5 | 2006 | 94 | 0.230 |
Why?
|
Quality Control | 8 | 2015 | 841 | 0.230 |
Why?
|
Clotrimazole | 4 | 1996 | 77 | 0.230 |
Why?
|
Guidelines as Topic | 7 | 2014 | 1404 | 0.230 |
Why?
|
Fibrin Tissue Adhesive | 1 | 2003 | 85 | 0.230 |
Why?
|
Antioxidants | 9 | 2004 | 1658 | 0.230 |
Why?
|
Intercellular Signaling Peptides and Proteins | 6 | 2005 | 1678 | 0.220 |
Why?
|
Adipose Tissue | 6 | 2019 | 3280 | 0.220 |
Why?
|
Mass Screening | 6 | 2008 | 5251 | 0.220 |
Why?
|
Electrocoagulation | 1 | 2003 | 158 | 0.220 |
Why?
|
Blood Glucose | 14 | 2015 | 6259 | 0.220 |
Why?
|
Acute-Phase Reaction | 2 | 2001 | 92 | 0.220 |
Why?
|
Chylothorax | 1 | 2003 | 84 | 0.220 |
Why?
|
Razoxane | 3 | 2012 | 44 | 0.220 |
Why?
|
Practice Guidelines as Topic | 7 | 2015 | 7270 | 0.220 |
Why?
|
Insulin | 15 | 2016 | 6584 | 0.220 |
Why?
|
Body Mass Index | 36 | 2016 | 12718 | 0.220 |
Why?
|
Vitamin E | 8 | 2009 | 868 | 0.210 |
Why?
|
Aldosterone | 4 | 2013 | 877 | 0.210 |
Why?
|
Postprandial Period | 4 | 2016 | 293 | 0.210 |
Why?
|
Receptors, Tumor Necrosis Factor | 9 | 2008 | 595 | 0.210 |
Why?
|
Myocardial Reperfusion | 2 | 2001 | 351 | 0.210 |
Why?
|
Hypolipidemic Agents | 3 | 2020 | 606 | 0.210 |
Why?
|
Uremia | 1 | 2003 | 200 | 0.210 |
Why?
|
Multivariate Analysis | 30 | 2015 | 12243 | 0.210 |
Why?
|
Hypertension | 18 | 2015 | 8480 | 0.210 |
Why?
|
Running | 3 | 2006 | 479 | 0.200 |
Why?
|
CD40 Ligand | 4 | 2008 | 526 | 0.200 |
Why?
|
Lipoproteins, LDL | 5 | 2009 | 642 | 0.200 |
Why?
|
Cardiomyopathies | 5 | 2012 | 1911 | 0.200 |
Why?
|
District of Columbia | 6 | 2000 | 157 | 0.200 |
Why?
|
Dietary Fats | 8 | 2005 | 2016 | 0.200 |
Why?
|
Ferritins | 5 | 2008 | 590 | 0.200 |
Why?
|
beta 2-Microglobulin | 3 | 1994 | 315 | 0.200 |
Why?
|
Swimming | 2 | 1999 | 205 | 0.200 |
Why?
|
Cardiology | 1 | 2013 | 1668 | 0.200 |
Why?
|
Colorectal Neoplasms | 10 | 2016 | 6773 | 0.200 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 627 | 0.200 |
Why?
|
Sports | 2 | 1999 | 688 | 0.200 |
Why?
|
Alcohol Drinking | 12 | 2009 | 3965 | 0.190 |
Why?
|
Follow-Up Studies | 45 | 2019 | 39001 | 0.190 |
Why?
|
Sex Factors | 17 | 2012 | 10394 | 0.190 |
Why?
|
History, 21st Century | 3 | 2016 | 1532 | 0.190 |
Why?
|
Bicycling | 2 | 1999 | 176 | 0.190 |
Why?
|
Doxorubicin | 6 | 2012 | 2234 | 0.190 |
Why?
|
Myelin P2 Protein | 1 | 2000 | 20 | 0.190 |
Why?
|
United States | 47 | 2016 | 69859 | 0.190 |
Why?
|
Transferrin | 7 | 2008 | 295 | 0.190 |
Why?
|
Algorithms | 6 | 2013 | 13869 | 0.190 |
Why?
|
Peptide Fragments | 5 | 2013 | 5096 | 0.190 |
Why?
|
Resistin | 2 | 2013 | 170 | 0.190 |
Why?
|
Cardiotonic Agents | 2 | 2012 | 535 | 0.190 |
Why?
|
Echocardiography | 6 | 2012 | 5096 | 0.190 |
Why?
|
Reproducibility of Results | 17 | 2015 | 19894 | 0.180 |
Why?
|
Proteins | 3 | 2012 | 6098 | 0.180 |
Why?
|
History, 19th Century | 2 | 2015 | 720 | 0.180 |
Why?
|
Cohort Studies | 48 | 2013 | 40545 | 0.180 |
Why?
|
Vitamin D | 4 | 2016 | 3222 | 0.180 |
Why?
|
Creatine Kinase | 7 | 2006 | 694 | 0.180 |
Why?
|
Protoporphyrins | 2 | 2013 | 164 | 0.180 |
Why?
|
Kidney Failure, Chronic | 4 | 2008 | 2534 | 0.180 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2015 | 2200 | 0.180 |
Why?
|
Feeding Behavior | 8 | 2016 | 3187 | 0.180 |
Why?
|
Diet | 12 | 2016 | 7930 | 0.180 |
Why?
|
Helicobacter pylori | 1 | 2023 | 384 | 0.180 |
Why?
|
Aspirin | 8 | 2016 | 3283 | 0.180 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2023 | 1344 | 0.180 |
Why?
|
Lipid Metabolism | 3 | 2016 | 1885 | 0.180 |
Why?
|
Helicobacter Infections | 1 | 2023 | 388 | 0.180 |
Why?
|
Body Composition | 5 | 2019 | 2401 | 0.170 |
Why?
|
Apolipoproteins E | 5 | 1988 | 1436 | 0.170 |
Why?
|
Creatine Kinase, MB Form | 5 | 2008 | 214 | 0.170 |
Why?
|
P-Selectin | 2 | 2002 | 601 | 0.170 |
Why?
|
Adrenal Hyperplasia, Congenital | 1 | 1999 | 98 | 0.170 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2012 | 1520 | 0.170 |
Why?
|
Electrocardiography | 7 | 2010 | 6441 | 0.170 |
Why?
|
Child, Preschool | 30 | 2012 | 40964 | 0.170 |
Why?
|
Sex Characteristics | 7 | 2016 | 2583 | 0.170 |
Why?
|
Valine | 3 | 2013 | 413 | 0.170 |
Why?
|
Health Surveys | 8 | 2011 | 4036 | 0.170 |
Why?
|
alpha-Cyclodextrins | 1 | 1998 | 11 | 0.170 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2015 | 4422 | 0.160 |
Why?
|
Methylmalonic Acid | 1 | 1998 | 49 | 0.160 |
Why?
|
Arginine | 3 | 2015 | 943 | 0.160 |
Why?
|
Communication | 1 | 2012 | 3748 | 0.160 |
Why?
|
Apolipoprotein A-I | 6 | 2006 | 281 | 0.160 |
Why?
|
Coronary Artery Disease | 6 | 2013 | 6485 | 0.160 |
Why?
|
Adenoma | 5 | 2009 | 2173 | 0.160 |
Why?
|
Bupivacaine | 2 | 2001 | 411 | 0.160 |
Why?
|
National Health Programs | 1 | 2002 | 445 | 0.160 |
Why?
|
Receptors, Adiponectin | 2 | 2023 | 82 | 0.160 |
Why?
|
Prognosis | 28 | 2019 | 29052 | 0.160 |
Why?
|
Smoking | 20 | 2009 | 8984 | 0.160 |
Why?
|
Adolescent | 35 | 2012 | 85729 | 0.160 |
Why?
|
Prostatism | 2 | 2008 | 14 | 0.160 |
Why?
|
Polymorphism, Single Nucleotide | 11 | 2023 | 15518 | 0.160 |
Why?
|
Anesthetics, Local | 3 | 2001 | 985 | 0.150 |
Why?
|
Urethritis | 1 | 2017 | 23 | 0.150 |
Why?
|
Carrier Proteins | 3 | 2001 | 5021 | 0.150 |
Why?
|
beta Carotene | 4 | 2004 | 527 | 0.150 |
Why?
|
Cystic Fibrosis | 2 | 1996 | 1178 | 0.150 |
Why?
|
Myocardial Contraction | 2 | 2003 | 1579 | 0.150 |
Why?
|
Antibiotics, Antineoplastic | 3 | 2012 | 690 | 0.150 |
Why?
|
Spectrophotometry, Ultraviolet | 4 | 2002 | 220 | 0.150 |
Why?
|
Prostate-Specific Antigen | 4 | 2017 | 2471 | 0.150 |
Why?
|
Ketoprofen | 1 | 1997 | 8 | 0.150 |
Why?
|
Renin-Angiotensin System | 3 | 2013 | 758 | 0.150 |
Why?
|
Propylene Glycols | 2 | 1994 | 92 | 0.150 |
Why?
|
Biological Assay | 3 | 2014 | 650 | 0.150 |
Why?
|
Hemoglobins | 2 | 2000 | 1531 | 0.150 |
Why?
|
Child | 37 | 2013 | 77637 | 0.150 |
Why?
|
Nutrition Surveys | 7 | 2012 | 1660 | 0.150 |
Why?
|
Angola | 1 | 2016 | 16 | 0.150 |
Why?
|
Aged, 80 and over | 33 | 2016 | 57744 | 0.150 |
Why?
|
Cross-Sectional Studies | 32 | 2023 | 25032 | 0.150 |
Why?
|
Prostatitis | 1 | 2017 | 102 | 0.150 |
Why?
|
Authorship | 3 | 2009 | 271 | 0.150 |
Why?
|
Dehydroepiandrosterone Sulfate | 3 | 2008 | 237 | 0.150 |
Why?
|
Logistic Models | 20 | 2015 | 13404 | 0.150 |
Why?
|
Infectious Mononucleosis | 1 | 2017 | 131 | 0.140 |
Why?
|
Human Growth Hormone | 3 | 2012 | 684 | 0.140 |
Why?
|
Neopterin | 4 | 2012 | 56 | 0.140 |
Why?
|
Statistics, Nonparametric | 9 | 2012 | 2883 | 0.140 |
Why?
|
Anthropometry | 7 | 2006 | 1348 | 0.140 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 3 | 2006 | 123 | 0.140 |
Why?
|
Consensus | 4 | 2020 | 2954 | 0.140 |
Why?
|
Receptors, Interleukin-6 | 2 | 2008 | 225 | 0.140 |
Why?
|
Immunosuppressive Agents | 2 | 2002 | 4152 | 0.140 |
Why?
|
Ink | 1 | 2016 | 44 | 0.140 |
Why?
|
Paper | 1 | 2016 | 85 | 0.140 |
Why?
|
Stroke | 7 | 2023 | 9975 | 0.140 |
Why?
|
Exercise | 9 | 2005 | 5611 | 0.140 |
Why?
|
Digoxigenin | 1 | 1995 | 26 | 0.140 |
Why?
|
Reactive Oxygen Species | 3 | 2009 | 2077 | 0.140 |
Why?
|
Infant, Newborn | 16 | 2012 | 25609 | 0.140 |
Why?
|
Gonadotropins, Pituitary | 1 | 1995 | 73 | 0.140 |
Why?
|
Vitamin A | 4 | 2004 | 615 | 0.140 |
Why?
|
Iron, Dietary | 3 | 2008 | 141 | 0.130 |
Why?
|
Linear Models | 13 | 2013 | 5952 | 0.130 |
Why?
|
Saponins | 1 | 1995 | 50 | 0.130 |
Why?
|
Itraconazole | 1 | 1995 | 43 | 0.130 |
Why?
|
Asparaginase | 1 | 1997 | 236 | 0.130 |
Why?
|
Pyruvate Carboxylase Deficiency Disease | 1 | 1995 | 2 | 0.130 |
Why?
|
Point-of-Care Systems | 2 | 2001 | 1177 | 0.130 |
Why?
|
Chemical Precipitation | 4 | 2001 | 179 | 0.130 |
Why?
|
Dehydroepiandrosterone | 2 | 2008 | 251 | 0.130 |
Why?
|
Sirolimus | 1 | 2002 | 1565 | 0.130 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 452 | 0.130 |
Why?
|
Radioligand Assay | 2 | 1992 | 374 | 0.130 |
Why?
|
Educational Status | 1 | 2023 | 2540 | 0.130 |
Why?
|
Neonatal Screening | 1 | 1999 | 590 | 0.130 |
Why?
|
Creatinine | 9 | 2015 | 1918 | 0.130 |
Why?
|
Estrogen Replacement Therapy | 4 | 2008 | 1203 | 0.130 |
Why?
|
Tetrazoles | 3 | 2013 | 834 | 0.130 |
Why?
|
Ibuprofen | 1 | 1996 | 236 | 0.130 |
Why?
|
Spectrometry, Fluorescence | 2 | 2007 | 688 | 0.130 |
Why?
|
Electrophoresis | 3 | 2002 | 240 | 0.130 |
Why?
|
Neoplasm Proteins | 2 | 2013 | 3706 | 0.120 |
Why?
|
Life Style | 15 | 2009 | 3833 | 0.120 |
Why?
|
Hyperinsulinism | 3 | 2010 | 414 | 0.120 |
Why?
|
Hematocrit | 2 | 2012 | 636 | 0.120 |
Why?
|
Digoxin | 1 | 1995 | 250 | 0.120 |
Why?
|
Adrenergic beta-Agonists | 3 | 2006 | 346 | 0.120 |
Why?
|
Odds Ratio | 15 | 2015 | 9848 | 0.120 |
Why?
|
Cholecalciferol | 2 | 2023 | 536 | 0.120 |
Why?
|
Thyroid Hormones | 2 | 2001 | 389 | 0.120 |
Why?
|
Interleukin-1beta | 3 | 2022 | 973 | 0.120 |
Why?
|
Urban Population | 3 | 2000 | 2021 | 0.120 |
Why?
|
Proinsulin | 2 | 2005 | 133 | 0.120 |
Why?
|
Ascorbic Acid | 3 | 2004 | 650 | 0.120 |
Why?
|
E-Selectin | 6 | 2007 | 579 | 0.120 |
Why?
|
Body Size | 3 | 2012 | 461 | 0.120 |
Why?
|
Prostatic Neoplasms | 10 | 2016 | 11059 | 0.120 |
Why?
|
Incidence | 21 | 2011 | 20948 | 0.120 |
Why?
|
Neoplasms | 5 | 2013 | 21675 | 0.120 |
Why?
|
Family Health | 1 | 1999 | 1280 | 0.120 |
Why?
|
Glomerular Filtration Rate | 5 | 2015 | 2167 | 0.120 |
Why?
|
Dietary Supplements | 7 | 2015 | 3292 | 0.120 |
Why?
|
South Africa | 2 | 2016 | 1731 | 0.120 |
Why?
|
Immunoenzyme Techniques | 3 | 2006 | 1799 | 0.120 |
Why?
|
Genetic Variation | 7 | 2008 | 6535 | 0.120 |
Why?
|
Chlamydia Infections | 1 | 2017 | 365 | 0.120 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2015 | 214 | 0.110 |
Why?
|
Fumarates | 2 | 2013 | 132 | 0.110 |
Why?
|
Trans Fatty Acids | 2 | 2005 | 153 | 0.110 |
Why?
|
Time Factors | 19 | 2016 | 40038 | 0.110 |
Why?
|
Infant | 19 | 2011 | 35122 | 0.110 |
Why?
|
Cyclosporine | 1 | 1996 | 788 | 0.110 |
Why?
|
von Willebrand Factor | 2 | 2015 | 669 | 0.110 |
Why?
|
Fluorescence Polarization Immunoassay | 2 | 2005 | 9 | 0.110 |
Why?
|
Societies | 2 | 2012 | 104 | 0.110 |
Why?
|
Gonorrhea | 1 | 2017 | 335 | 0.110 |
Why?
|
Laboratories, Hospital | 1 | 2014 | 194 | 0.110 |
Why?
|
Menopause | 7 | 2008 | 1626 | 0.110 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 1995 | 494 | 0.110 |
Why?
|
Anemia, Sickle Cell | 3 | 1996 | 1020 | 0.110 |
Why?
|
False Negative Reactions | 2 | 2008 | 588 | 0.110 |
Why?
|
History, 20th Century | 2 | 2015 | 2736 | 0.110 |
Why?
|
Folic Acid | 4 | 2007 | 1293 | 0.110 |
Why?
|
Smell | 1 | 2014 | 244 | 0.110 |
Why?
|
Arterial Occlusive Diseases | 2 | 2008 | 793 | 0.110 |
Why?
|
Heart | 6 | 2012 | 4460 | 0.110 |
Why?
|
Tacrolimus | 1 | 1996 | 743 | 0.100 |
Why?
|
Keto Acids | 1 | 1992 | 34 | 0.100 |
Why?
|
Organizational Innovation | 1 | 2015 | 559 | 0.100 |
Why?
|
Drug Stability | 3 | 1998 | 291 | 0.100 |
Why?
|
Thyroxine | 1 | 1995 | 667 | 0.100 |
Why?
|
Amlodipine | 1 | 2012 | 83 | 0.100 |
Why?
|
Evaluation Studies as Topic | 5 | 1999 | 1677 | 0.100 |
Why?
|
Endostatins | 1 | 2012 | 174 | 0.100 |
Why?
|
Myocardial Ischemia | 5 | 2007 | 2150 | 0.100 |
Why?
|
Myocytes, Cardiac | 4 | 2008 | 1631 | 0.100 |
Why?
|
Triiodothyronine | 2 | 2008 | 494 | 0.100 |
Why?
|
Lovastatin | 2 | 2002 | 120 | 0.100 |
Why?
|
Pediatrics | 4 | 2007 | 3474 | 0.100 |
Why?
|
Biology | 1 | 2014 | 295 | 0.100 |
Why?
|
Pregnancy Proteins | 1 | 2012 | 229 | 0.100 |
Why?
|
Solutions | 2 | 2002 | 426 | 0.100 |
Why?
|
Acute Disease | 12 | 2007 | 7150 | 0.100 |
Why?
|
Isoenzymes | 5 | 2004 | 1728 | 0.100 |
Why?
|
Ethics Committees | 1 | 2010 | 54 | 0.100 |
Why?
|
Androgens | 3 | 2007 | 1247 | 0.100 |
Why?
|
Protein Isoforms | 3 | 2006 | 1729 | 0.090 |
Why?
|
Potassium Channel Blockers | 3 | 1996 | 171 | 0.090 |
Why?
|
Calibration | 5 | 2009 | 816 | 0.090 |
Why?
|
Antifungal Agents | 1 | 1995 | 729 | 0.090 |
Why?
|
Ecuador | 3 | 2013 | 55 | 0.090 |
Why?
|
Interleukin-18 | 2 | 2012 | 249 | 0.090 |
Why?
|
Recurrence | 13 | 2013 | 8337 | 0.090 |
Why?
|
Tyrosine | 2 | 2006 | 1462 | 0.090 |
Why?
|
Disease-Free Survival | 6 | 2013 | 6895 | 0.090 |
Why?
|
Blood Gas Analysis | 1 | 1992 | 383 | 0.090 |
Why?
|
Office Visits | 2 | 1993 | 598 | 0.090 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2012 | 272 | 0.090 |
Why?
|
Luminescent Measurements | 3 | 2003 | 405 | 0.090 |
Why?
|
History, Ancient | 1 | 2010 | 211 | 0.090 |
Why?
|
Hyperlipoproteinemia Type II | 2 | 2006 | 375 | 0.090 |
Why?
|
Radioimmunoassay | 4 | 2001 | 916 | 0.090 |
Why?
|
Myocardium | 6 | 2006 | 4775 | 0.090 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2010 | 169 | 0.090 |
Why?
|
Hypertrophy, Left Ventricular | 3 | 2004 | 858 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 14 | 2013 | 9944 | 0.090 |
Why?
|
Enalapril | 1 | 2012 | 327 | 0.090 |
Why?
|
Abdominal Fat | 1 | 2012 | 223 | 0.090 |
Why?
|
Indicators and Reagents | 3 | 2002 | 462 | 0.090 |
Why?
|
Diabetic Nephropathies | 2 | 2008 | 984 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 1 | 2000 | 2850 | 0.090 |
Why?
|
Brachial Artery | 4 | 2004 | 369 | 0.090 |
Why?
|
United Nations | 1 | 2010 | 165 | 0.090 |
Why?
|
Mathematics | 3 | 1997 | 727 | 0.090 |
Why?
|
Maryland | 4 | 2012 | 276 | 0.090 |
Why?
|
Immunoglobulin E | 1 | 1995 | 1463 | 0.090 |
Why?
|
Hormone Replacement Therapy | 5 | 2002 | 708 | 0.090 |
Why?
|
Diabetes Complications | 2 | 2011 | 1360 | 0.090 |
Why?
|
Protein Precursors | 4 | 2006 | 1154 | 0.090 |
Why?
|
Bilirubin | 3 | 2000 | 425 | 0.090 |
Why?
|
Societies, Scientific | 1 | 2010 | 220 | 0.090 |
Why?
|
Muscle, Skeletal | 2 | 2019 | 4925 | 0.090 |
Why?
|
Acute-Phase Proteins | 3 | 2005 | 262 | 0.090 |
Why?
|
Heart Failure | 7 | 2023 | 10896 | 0.090 |
Why?
|
Proteomics | 3 | 2014 | 3639 | 0.090 |
Why?
|
Physical Fitness | 4 | 2005 | 732 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2005 | 1366 | 0.080 |
Why?
|
Insulin Resistance | 5 | 2007 | 3863 | 0.080 |
Why?
|
Analysis of Variance | 8 | 2010 | 6356 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 3 | 2004 | 264 | 0.080 |
Why?
|
Coronary Thrombosis | 1 | 2012 | 495 | 0.080 |
Why?
|
Blood Coagulation | 1 | 1994 | 1127 | 0.080 |
Why?
|
Motivation | 1 | 2018 | 1971 | 0.080 |
Why?
|
Diabetic Ketoacidosis | 1 | 1992 | 247 | 0.080 |
Why?
|
Linkage Disequilibrium | 3 | 2009 | 1996 | 0.080 |
Why?
|
Apoprotein(a) | 2 | 2006 | 18 | 0.080 |
Why?
|
Blood Donors | 2 | 2001 | 355 | 0.080 |
Why?
|
Trazodone | 1 | 1988 | 66 | 0.080 |
Why?
|
Plagiarism | 1 | 2008 | 22 | 0.080 |
Why?
|
Vitamin B 12 | 3 | 2007 | 527 | 0.080 |
Why?
|
Type A Personality | 1 | 1987 | 25 | 0.080 |
Why?
|
Tissue Plasminogen Activator | 3 | 2013 | 1263 | 0.080 |
Why?
|
Patient Education as Topic | 2 | 2002 | 2278 | 0.080 |
Why?
|
Apolipoprotein C-III | 2 | 2006 | 202 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2210 | 0.080 |
Why?
|
Solubility | 6 | 2008 | 1088 | 0.080 |
Why?
|
Age Factors | 9 | 2008 | 18355 | 0.080 |
Why?
|
Information Dissemination | 2 | 2015 | 1099 | 0.080 |
Why?
|
Blood Specimen Collection | 3 | 2004 | 246 | 0.080 |
Why?
|
Program Evaluation | 1 | 1996 | 2483 | 0.080 |
Why?
|
Treatment Outcome | 12 | 2023 | 63042 | 0.080 |
Why?
|
Activities of Daily Living | 2 | 2008 | 2419 | 0.080 |
Why?
|
Apolipoprotein B-100 | 3 | 2004 | 148 | 0.080 |
Why?
|
Thrombosis | 4 | 2008 | 2968 | 0.080 |
Why?
|
Thyroid Function Tests | 1 | 2008 | 286 | 0.080 |
Why?
|
Androstane-3,17-diol | 1 | 2007 | 19 | 0.080 |
Why?
|
Behavior, Animal | 2 | 2014 | 1880 | 0.080 |
Why?
|
Anticonvulsants | 2 | 1994 | 1910 | 0.080 |
Why?
|
Retinol-Binding Proteins | 3 | 1996 | 65 | 0.070 |
Why?
|
Carbon Dioxide | 1 | 1992 | 1150 | 0.070 |
Why?
|
Frail Elderly | 1 | 2012 | 693 | 0.070 |
Why?
|
Statistics as Topic | 4 | 2017 | 2369 | 0.070 |
Why?
|
Siberia | 1 | 2006 | 32 | 0.070 |
Why?
|
Hyperglycemia | 2 | 2007 | 1373 | 0.070 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2018 | 1637 | 0.070 |
Why?
|
Genotype | 11 | 2011 | 12944 | 0.070 |
Why?
|
Nuts | 1 | 2009 | 257 | 0.070 |
Why?
|
Atrial Natriuretic Factor | 2 | 2013 | 393 | 0.070 |
Why?
|
Apolipoproteins C | 1 | 1986 | 59 | 0.070 |
Why?
|
Mortality | 2 | 2010 | 2862 | 0.070 |
Why?
|
Syndrome | 8 | 2007 | 3249 | 0.070 |
Why?
|
Cadmium | 1 | 2008 | 212 | 0.070 |
Why?
|
Energy Intake | 5 | 2005 | 2149 | 0.070 |
Why?
|
Ventricular Function, Left | 5 | 2013 | 3660 | 0.070 |
Why?
|
Dietary Fiber | 3 | 2005 | 759 | 0.070 |
Why?
|
Alanine | 4 | 2007 | 571 | 0.070 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2008 | 275 | 0.070 |
Why?
|
Dihydrotestosterone | 1 | 2007 | 185 | 0.070 |
Why?
|
Cardiovascular Agents | 2 | 2004 | 850 | 0.070 |
Why?
|
Absorptiometry, Photon | 1 | 2012 | 1725 | 0.070 |
Why?
|
Oxidative Stress | 8 | 2007 | 3082 | 0.070 |
Why?
|
Lung Diseases | 1 | 1996 | 1887 | 0.070 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 1516 | 0.070 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2009 | 3758 | 0.070 |
Why?
|
Sodium | 3 | 2006 | 1622 | 0.070 |
Why?
|
Stroke Volume | 1 | 1999 | 5002 | 0.070 |
Why?
|
Retinol-Binding Proteins, Plasma | 2 | 2016 | 93 | 0.070 |
Why?
|
Vitamin B 6 | 1 | 2007 | 236 | 0.070 |
Why?
|
Hospitals, Private | 1 | 2006 | 63 | 0.070 |
Why?
|
ABO Blood-Group System | 1 | 2008 | 367 | 0.070 |
Why?
|
Intermittent Claudication | 1 | 2008 | 309 | 0.070 |
Why?
|
Myocarditis | 2 | 2007 | 768 | 0.070 |
Why?
|
Artifacts | 2 | 2008 | 1904 | 0.070 |
Why?
|
Proportional Hazards Models | 10 | 2013 | 12354 | 0.070 |
Why?
|
Environmental Exposure | 1 | 2000 | 4232 | 0.070 |
Why?
|
Cytokines | 3 | 2018 | 7324 | 0.070 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 284 | 0.070 |
Why?
|
Isoproterenol | 1 | 2006 | 399 | 0.070 |
Why?
|
Europe | 3 | 2016 | 3336 | 0.070 |
Why?
|
Phospholipids | 1 | 2009 | 784 | 0.070 |
Why?
|
Data Interpretation, Statistical | 3 | 2012 | 2715 | 0.070 |
Why?
|
Sheep | 1 | 2008 | 1437 | 0.070 |
Why?
|
Estrogens | 4 | 2007 | 1563 | 0.070 |
Why?
|
Depressive Disorder, Major | 1 | 2023 | 4635 | 0.070 |
Why?
|
Adenoma, Bile Duct | 1 | 1984 | 30 | 0.060 |
Why?
|
Hyperlipidemia, Familial Combined | 1 | 2004 | 10 | 0.060 |
Why?
|
Hypopituitarism | 1 | 2007 | 254 | 0.060 |
Why?
|
Animals | 21 | 2014 | 168660 | 0.060 |
Why?
|
F2-Isoprostanes | 1 | 2004 | 35 | 0.060 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2006 | 211 | 0.060 |
Why?
|
Diabetes Mellitus | 7 | 2015 | 5752 | 0.060 |
Why?
|
Ventricular Function | 1 | 2006 | 415 | 0.060 |
Why?
|
Natriuresis | 1 | 2004 | 124 | 0.060 |
Why?
|
Peroxidase | 1 | 2008 | 611 | 0.060 |
Why?
|
Risk Reduction Behavior | 2 | 2009 | 1125 | 0.060 |
Why?
|
Vitamin B Complex | 1 | 2007 | 288 | 0.060 |
Why?
|
Alcohol Dehydrogenase | 1 | 2005 | 119 | 0.060 |
Why?
|
Malondialdehyde | 1 | 2004 | 105 | 0.060 |
Why?
|
Antihypertensive Agents | 2 | 2012 | 2047 | 0.060 |
Why?
|
Ticlopidine | 1 | 2010 | 899 | 0.060 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2010 | 3070 | 0.060 |
Why?
|
Placebos | 4 | 2013 | 1674 | 0.060 |
Why?
|
Fibroblasts | 1 | 1995 | 4162 | 0.060 |
Why?
|
Myelin Sheath | 2 | 1987 | 652 | 0.060 |
Why?
|
Women's Health | 3 | 2011 | 2033 | 0.060 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2007 | 1874 | 0.060 |
Why?
|
Pyridazines | 1 | 2006 | 202 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2013 | 1342 | 0.060 |
Why?
|
Argon | 1 | 2003 | 36 | 0.060 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2004 | 96 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 1411 | 0.060 |
Why?
|
Coronary Angiography | 5 | 2008 | 4576 | 0.060 |
Why?
|
Phosphotungstic Acid | 2 | 1997 | 6 | 0.060 |
Why?
|
Disease Progression | 6 | 2018 | 13273 | 0.060 |
Why?
|
Polyhydramnios | 1 | 2003 | 41 | 0.060 |
Why?
|
Research Personnel | 1 | 2008 | 573 | 0.060 |
Why?
|
Simvastatin | 1 | 2006 | 360 | 0.060 |
Why?
|
Heat-Shock Proteins | 1 | 2007 | 820 | 0.060 |
Why?
|
ROC Curve | 6 | 2009 | 3527 | 0.060 |
Why?
|
Hypoglycemic Agents | 4 | 2009 | 2877 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2012 | 3205 | 0.060 |
Why?
|
Child Mortality | 1 | 2005 | 198 | 0.060 |
Why?
|
Blood Urea Nitrogen | 1 | 2003 | 191 | 0.060 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2006 | 689 | 0.060 |
Why?
|
Secondary Prevention | 5 | 2012 | 1529 | 0.060 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 1984 | 295 | 0.060 |
Why?
|
Hematologic Tests | 1 | 2004 | 240 | 0.060 |
Why?
|
Primary Prevention | 2 | 2008 | 1167 | 0.060 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2004 | 364 | 0.060 |
Why?
|
Muscle Strength | 1 | 2007 | 592 | 0.060 |
Why?
|
Lipase | 1 | 2005 | 314 | 0.060 |
Why?
|
Body Constitution | 2 | 2004 | 278 | 0.060 |
Why?
|
Vitamins | 2 | 2005 | 1622 | 0.050 |
Why?
|
Cardiovascular System | 2 | 2012 | 828 | 0.050 |
Why?
|
Likelihood Functions | 2 | 2008 | 1004 | 0.050 |
Why?
|
Mineral Oil | 1 | 2022 | 25 | 0.050 |
Why?
|
Dietary Carbohydrates | 2 | 2005 | 906 | 0.050 |
Why?
|
Selenium | 1 | 2005 | 405 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2010 | 10940 | 0.050 |
Why?
|
Hamartoma | 1 | 1984 | 238 | 0.050 |
Why?
|
Fructose | 1 | 2004 | 287 | 0.050 |
Why?
|
Heme | 3 | 2013 | 306 | 0.050 |
Why?
|
Boston | 3 | 2006 | 9310 | 0.050 |
Why?
|
Peritoneal Dialysis | 1 | 2003 | 147 | 0.050 |
Why?
|
Metformin | 1 | 2009 | 837 | 0.050 |
Why?
|
Micronutrients | 1 | 2005 | 375 | 0.050 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2008 | 641 | 0.050 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2008 | 3338 | 0.050 |
Why?
|
Leg | 1 | 2007 | 1116 | 0.050 |
Why?
|
Caloric Restriction | 1 | 2004 | 302 | 0.050 |
Why?
|
Kidney Glomerulus | 1 | 2005 | 697 | 0.050 |
Why?
|
Mannose-Binding Lectins | 2 | 2001 | 100 | 0.050 |
Why?
|
Diagnosis-Related Groups | 1 | 2004 | 455 | 0.050 |
Why?
|
Eating | 3 | 2001 | 1536 | 0.050 |
Why?
|
Prevalence | 4 | 2012 | 15211 | 0.050 |
Why?
|
Rats | 10 | 2006 | 24250 | 0.050 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2022 | 127 | 0.050 |
Why?
|
Telomere | 1 | 2008 | 910 | 0.050 |
Why?
|
Erythrocytes | 3 | 1996 | 2455 | 0.050 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2023 | 176 | 0.050 |
Why?
|
Thoracotomy | 1 | 2003 | 363 | 0.050 |
Why?
|
Pyridines | 2 | 2006 | 2827 | 0.050 |
Why?
|
Immunoglobulin G | 3 | 2009 | 4561 | 0.050 |
Why?
|
Homocystine | 1 | 2001 | 22 | 0.050 |
Why?
|
Hospitals | 1 | 2015 | 3953 | 0.050 |
Why?
|
Survival Rate | 7 | 2019 | 12786 | 0.050 |
Why?
|
Pilot Projects | 4 | 2012 | 8316 | 0.050 |
Why?
|
Peptides | 1 | 2014 | 4406 | 0.050 |
Why?
|
Rats, Inbred SHR | 4 | 2006 | 195 | 0.050 |
Why?
|
Mitoxantrone | 1 | 2001 | 152 | 0.050 |
Why?
|
Societies, Medical | 3 | 2020 | 3740 | 0.050 |
Why?
|
Postural Balance | 1 | 2006 | 621 | 0.050 |
Why?
|
Diet, Reducing | 1 | 2004 | 462 | 0.050 |
Why?
|
London | 1 | 2021 | 233 | 0.050 |
Why?
|
Hawaii | 1 | 2001 | 105 | 0.050 |
Why?
|
Receptors, Cell Surface | 2 | 2008 | 2865 | 0.050 |
Why?
|
Cystatins | 1 | 2001 | 55 | 0.050 |
Why?
|
Exercise Tolerance | 1 | 2006 | 768 | 0.050 |
Why?
|
Hyperaldosteronism | 1 | 2004 | 240 | 0.050 |
Why?
|
Nurses | 6 | 2006 | 2461 | 0.050 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2001 | 129 | 0.050 |
Why?
|
Enoxaparin | 2 | 2000 | 377 | 0.050 |
Why?
|
Terbutaline | 1 | 2000 | 23 | 0.050 |
Why?
|
Aging | 4 | 2012 | 8655 | 0.050 |
Why?
|
Infant, Very Low Birth Weight | 1 | 2003 | 404 | 0.050 |
Why?
|
Esophageal Atresia | 1 | 2003 | 201 | 0.050 |
Why?
|
Sciatic Nerve | 2 | 1998 | 607 | 0.050 |
Why?
|
Chylomicrons | 1 | 2000 | 26 | 0.050 |
Why?
|
Hemostasis | 1 | 2003 | 458 | 0.050 |
Why?
|
Immunochemistry | 3 | 1989 | 124 | 0.050 |
Why?
|
Receptors, Transferrin | 3 | 2008 | 296 | 0.050 |
Why?
|
Vasodilation | 3 | 2015 | 944 | 0.050 |
Why?
|
Latex | 1 | 1999 | 52 | 0.050 |
Why?
|
Longitudinal Studies | 6 | 2019 | 13980 | 0.050 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2003 | 546 | 0.040 |
Why?
|
Premenopause | 1 | 2004 | 1033 | 0.040 |
Why?
|
Internet | 1 | 2012 | 3058 | 0.040 |
Why?
|
Pyrrolidines | 3 | 2007 | 341 | 0.040 |
Why?
|
Gene Frequency | 4 | 2008 | 3585 | 0.040 |
Why?
|
Liver Failure | 1 | 2002 | 241 | 0.040 |
Why?
|
Detergents | 1 | 2000 | 230 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20121 | 0.040 |
Why?
|
Leukocytes | 1 | 2008 | 2044 | 0.040 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2002 | 506 | 0.040 |
Why?
|
Zinc | 1 | 2004 | 683 | 0.040 |
Why?
|
Kidney Function Tests | 2 | 2015 | 684 | 0.040 |
Why?
|
Confidence Intervals | 3 | 2012 | 2971 | 0.040 |
Why?
|
Insulin-Secreting Cells | 1 | 2007 | 889 | 0.040 |
Why?
|
Fluoroquinolones | 3 | 2007 | 308 | 0.040 |
Why?
|
Iron Overload | 3 | 2008 | 242 | 0.040 |
Why?
|
Surface-Active Agents | 1 | 2000 | 159 | 0.040 |
Why?
|
Exercise Test | 5 | 2008 | 2074 | 0.040 |
Why?
|
Bile Duct Neoplasms | 1 | 1984 | 567 | 0.040 |
Why?
|
Health | 1 | 2002 | 394 | 0.040 |
Why?
|
Altitude | 1 | 2000 | 161 | 0.040 |
Why?
|
Nutrition Assessment | 4 | 2005 | 723 | 0.040 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2023 | 604 | 0.040 |
Why?
|
Skinfold Thickness | 1 | 1999 | 162 | 0.040 |
Why?
|
Severity of Illness Index | 6 | 2015 | 15526 | 0.040 |
Why?
|
Cross-Over Studies | 4 | 2008 | 2029 | 0.040 |
Why?
|
Death, Sudden, Cardiac | 2 | 2010 | 1542 | 0.040 |
Why?
|
Cause of Death | 2 | 2008 | 3580 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2016 | 6363 | 0.040 |
Why?
|
Fibrinolytic Agents | 4 | 2004 | 2159 | 0.040 |
Why?
|
Comorbidity | 6 | 2015 | 10380 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2005 | 1055 | 0.040 |
Why?
|
Motor Activity | 1 | 2009 | 2714 | 0.040 |
Why?
|
Carcinoma, Basal Cell | 1 | 2004 | 545 | 0.040 |
Why?
|
Pregnancy | 7 | 2012 | 29140 | 0.040 |
Why?
|
Tobacco Smoke Pollution | 1 | 2004 | 816 | 0.040 |
Why?
|
Abdomen | 1 | 2004 | 1117 | 0.040 |
Why?
|
Vascular Diseases | 1 | 2007 | 1161 | 0.040 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2000 | 300 | 0.040 |
Why?
|
Growth Hormone | 1 | 2001 | 705 | 0.040 |
Why?
|
Membrane Proteins | 2 | 2005 | 7880 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2006 | 1582 | 0.040 |
Why?
|
Immune Sera | 1 | 1998 | 641 | 0.040 |
Why?
|
Cyclodextrins | 1 | 1998 | 57 | 0.040 |
Why?
|
Tamoxifen | 2 | 2001 | 981 | 0.040 |
Why?
|
Vitamin E Deficiency | 1 | 1998 | 32 | 0.040 |
Why?
|
Renal Dialysis | 2 | 2003 | 1783 | 0.040 |
Why?
|
Glycemic Index | 3 | 2005 | 394 | 0.040 |
Why?
|
Docosahexaenoic Acids | 1 | 2004 | 877 | 0.040 |
Why?
|
Cholesterol, VLDL | 2 | 2004 | 65 | 0.040 |
Why?
|
Polymorphism, Genetic | 2 | 2007 | 4326 | 0.040 |
Why?
|
Eicosapentaenoic Acid | 1 | 2022 | 581 | 0.040 |
Why?
|
Prenatal Care | 1 | 2005 | 1092 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 6 | 2016 | 17439 | 0.040 |
Why?
|
Vasculitis | 1 | 2002 | 519 | 0.040 |
Why?
|
Phenylcarbamates | 2 | 1994 | 38 | 0.040 |
Why?
|
Nuclear Family | 1 | 1999 | 318 | 0.040 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 1 | 1999 | 168 | 0.040 |
Why?
|
Vascular Patency | 1 | 2000 | 887 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3917 | 0.040 |
Why?
|
Monocytes | 1 | 2007 | 2593 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8430 | 0.040 |
Why?
|
Age Distribution | 3 | 2009 | 2899 | 0.040 |
Why?
|
Vitamin A Deficiency | 1 | 1998 | 101 | 0.040 |
Why?
|
Fathers | 1 | 2000 | 358 | 0.040 |
Why?
|
Antigens, Bacterial | 1 | 2023 | 1172 | 0.040 |
Why?
|
Sleep Deprivation | 1 | 2004 | 831 | 0.040 |
Why?
|
Immunodiffusion | 2 | 1986 | 163 | 0.040 |
Why?
|
Fruit | 1 | 2002 | 1141 | 0.040 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2005 | 2027 | 0.040 |
Why?
|
Postoperative Care | 1 | 2003 | 1485 | 0.040 |
Why?
|
HIV Infections | 3 | 2005 | 16715 | 0.040 |
Why?
|
Lipoprotein Lipase | 1 | 1997 | 127 | 0.040 |
Why?
|
Magnesium Chloride | 1 | 1996 | 32 | 0.040 |
Why?
|
Breast Neoplasms | 3 | 2013 | 20827 | 0.040 |
Why?
|
Heart Conduction System | 1 | 2002 | 1047 | 0.040 |
Why?
|
Immunologic Techniques | 2 | 1987 | 219 | 0.030 |
Why?
|
Arousal | 2 | 1994 | 1160 | 0.030 |
Why?
|
Aorta, Abdominal | 1 | 1999 | 646 | 0.030 |
Why?
|
Cardenolides | 1 | 1995 | 20 | 0.030 |
Why?
|
Cross Reactions | 2 | 1995 | 841 | 0.030 |
Why?
|
Prealbumin | 2 | 2008 | 207 | 0.030 |
Why?
|
Hydrochlorothiazide | 2 | 2006 | 98 | 0.030 |
Why?
|
Liver Diseases | 2 | 1999 | 1253 | 0.030 |
Why?
|
Administration, Oral | 6 | 2005 | 3912 | 0.030 |
Why?
|
Biological Transport, Active | 1 | 1996 | 349 | 0.030 |
Why?
|
Multiple Sclerosis | 2 | 1988 | 3079 | 0.030 |
Why?
|
Antisickling Agents | 1 | 1996 | 80 | 0.030 |
Why?
|
Tritium | 1 | 1996 | 745 | 0.030 |
Why?
|
Acetonitriles | 1 | 1995 | 53 | 0.030 |
Why?
|
Centrifugation | 1 | 1995 | 122 | 0.030 |
Why?
|
Antidepressive Agents | 1 | 1988 | 2837 | 0.030 |
Why?
|
Hyperbilirubinemia | 1 | 1995 | 77 | 0.030 |
Why?
|
Manganese | 1 | 1998 | 406 | 0.030 |
Why?
|
Protein Conformation | 1 | 2003 | 4009 | 0.030 |
Why?
|
Lower Extremity | 1 | 2003 | 1158 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 1999 | 2503 | 0.030 |
Why?
|
Lipoproteins, VLDL | 1 | 1996 | 201 | 0.030 |
Why?
|
Brain | 2 | 2016 | 26345 | 0.030 |
Why?
|
Bone Density | 1 | 2008 | 3460 | 0.030 |
Why?
|
Sampling Studies | 2 | 2008 | 622 | 0.030 |
Why?
|
Genome, Human | 1 | 2008 | 4418 | 0.030 |
Why?
|
Colitis, Ulcerative | 2 | 2005 | 1911 | 0.030 |
Why?
|
Mothers | 1 | 2005 | 2166 | 0.030 |
Why?
|
Weight Loss | 2 | 2004 | 2625 | 0.030 |
Why?
|
Weight Gain | 2 | 2005 | 2294 | 0.030 |
Why?
|
Antigen-Antibody Complex | 2 | 1987 | 517 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2012 | 5185 | 0.030 |
Why?
|
Circadian Rhythm | 3 | 2004 | 2620 | 0.030 |
Why?
|
Bronchopulmonary Dysplasia | 1 | 1998 | 305 | 0.030 |
Why?
|
Mexican Americans | 2 | 2007 | 165 | 0.030 |
Why?
|
Acetylglucosaminidase | 1 | 1994 | 70 | 0.030 |
Why?
|
Crohn Disease | 2 | 2005 | 2304 | 0.030 |
Why?
|
Single-Blind Method | 3 | 2004 | 1586 | 0.030 |
Why?
|
Survival Analysis | 4 | 2008 | 10251 | 0.030 |
Why?
|
Child Health Services | 1 | 2000 | 666 | 0.030 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2006 | 281 | 0.030 |
Why?
|
Olfactory Mucosa | 1 | 2014 | 98 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 2281 | 0.030 |
Why?
|
Lactates | 1 | 1995 | 431 | 0.030 |
Why?
|
Gestational Age | 2 | 2000 | 3488 | 0.030 |
Why?
|
Infant, Premature | 1 | 2003 | 2031 | 0.030 |
Why?
|
Young Adult | 7 | 2015 | 56392 | 0.030 |
Why?
|
Hospitalization | 3 | 2010 | 10259 | 0.030 |
Why?
|
Tocopherols | 2 | 2004 | 43 | 0.030 |
Why?
|
Prolactin | 1 | 1995 | 668 | 0.030 |
Why?
|
Hemolysis | 1 | 1995 | 420 | 0.030 |
Why?
|
Cysts | 1 | 1999 | 678 | 0.030 |
Why?
|
Acidosis, Lactic | 1 | 1995 | 142 | 0.030 |
Why?
|
Suburban Population | 1 | 1993 | 55 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 1 | 1995 | 745 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2004 | 2899 | 0.030 |
Why?
|
Virginia | 1 | 1993 | 121 | 0.030 |
Why?
|
Hospital Information Systems | 1 | 1995 | 395 | 0.030 |
Why?
|
Luteinizing Hormone | 1 | 1995 | 867 | 0.030 |
Why?
|
Free Radicals | 1 | 1993 | 237 | 0.030 |
Why?
|
Nutritional Status | 2 | 2003 | 1608 | 0.030 |
Why?
|
Magnetics | 1 | 1996 | 604 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2008 | 3655 | 0.030 |
Why?
|
Coronary Vessels | 2 | 2004 | 3106 | 0.030 |
Why?
|
HIV-1 | 1 | 1990 | 6939 | 0.030 |
Why?
|
Oxidants | 1 | 1993 | 164 | 0.030 |
Why?
|
Oxidation-Reduction | 2 | 2009 | 2183 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2001 | 1070 | 0.030 |
Why?
|
Animals, Newborn | 1 | 1998 | 2725 | 0.030 |
Why?
|
Thrombophilia | 1 | 2015 | 305 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 3 | 2008 | 6539 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 1998 | 1680 | 0.030 |
Why?
|
Free Radical Scavengers | 1 | 1993 | 216 | 0.030 |
Why?
|
Isotope Labeling | 1 | 2014 | 405 | 0.030 |
Why?
|
Brain Ischemia | 1 | 2006 | 3264 | 0.030 |
Why?
|
Drug Therapy, Combination | 3 | 2009 | 6487 | 0.030 |
Why?
|
Chromatography | 1 | 1992 | 206 | 0.030 |
Why?
|
Carotid Artery Diseases | 1 | 1998 | 875 | 0.030 |
Why?
|
Waist Circumference | 1 | 2016 | 917 | 0.030 |
Why?
|
Nerve Block | 1 | 1998 | 644 | 0.030 |
Why?
|
Maple Syrup Urine Disease | 1 | 1992 | 39 | 0.030 |
Why?
|
Cerebrovascular Disorders | 1 | 1999 | 1504 | 0.030 |
Why?
|
Argininosuccinic Aciduria | 1 | 1991 | 10 | 0.030 |
Why?
|
Calcium | 2 | 1995 | 5755 | 0.030 |
Why?
|
Particle Size | 2 | 2009 | 1639 | 0.030 |
Why?
|
Costa Rica | 2 | 2002 | 177 | 0.030 |
Why?
|
Hospital Administration | 1 | 2015 | 353 | 0.030 |
Why?
|
Osmolar Concentration | 1 | 2012 | 683 | 0.020 |
Why?
|
Public Health Practice | 2 | 2004 | 217 | 0.020 |
Why?
|
Calcinosis | 1 | 2000 | 1495 | 0.020 |
Why?
|
Creatine | 2 | 2006 | 421 | 0.020 |
Why?
|
Genetic Linkage | 2 | 2008 | 2419 | 0.020 |
Why?
|
Norepinephrine | 1 | 1994 | 909 | 0.020 |
Why?
|
Anemia | 2 | 2012 | 1502 | 0.020 |
Why?
|
Receptors, Interleukin-1 | 1 | 2012 | 262 | 0.020 |
Why?
|
Tanzania | 2 | 2005 | 1346 | 0.020 |
Why?
|
Drug Interactions | 1 | 1995 | 1460 | 0.020 |
Why?
|
Adenosine Triphosphatases | 1 | 1995 | 839 | 0.020 |
Why?
|
Epilepsies, Partial | 1 | 1994 | 435 | 0.020 |
Why?
|
Epinephrine | 1 | 1994 | 792 | 0.020 |
Why?
|
Biological Transport | 1 | 1995 | 2119 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 9440 | 0.020 |
Why?
|
Sample Size | 1 | 2013 | 841 | 0.020 |
Why?
|
Commerce | 1 | 2015 | 592 | 0.020 |
Why?
|
Factor Analysis, Statistical | 2 | 2004 | 975 | 0.020 |
Why?
|
Kidney | 1 | 2006 | 7185 | 0.020 |
Why?
|
Receptors, LDL | 1 | 1992 | 477 | 0.020 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 1991 | 235 | 0.020 |
Why?
|
Australia | 1 | 2013 | 1167 | 0.020 |
Why?
|
Insulin, Long-Acting | 1 | 2009 | 57 | 0.020 |
Why?
|
Lactic Acid | 1 | 1995 | 1131 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2023 | 3850 | 0.020 |
Why?
|
Dogs | 1 | 2014 | 3911 | 0.020 |
Why?
|
Disability Evaluation | 2 | 2008 | 1828 | 0.020 |
Why?
|
Sweetening Agents | 1 | 2012 | 295 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2000 | 7784 | 0.020 |
Why?
|
North America | 1 | 2013 | 1249 | 0.020 |
Why?
|
Diet Surveys | 2 | 2004 | 1173 | 0.020 |
Why?
|
Metabolism, Inborn Errors | 1 | 1991 | 288 | 0.020 |
Why?
|
Diastole | 2 | 2002 | 791 | 0.020 |
Why?
|
Succinimides | 1 | 1988 | 79 | 0.020 |
Why?
|
Molecular Weight | 1 | 2011 | 2253 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 1984 | 4251 | 0.020 |
Why?
|
Random Allocation | 3 | 2007 | 2429 | 0.020 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2012 | 637 | 0.020 |
Why?
|
Physicians | 2 | 2004 | 4569 | 0.020 |
Why?
|
Androstanes | 1 | 2008 | 21 | 0.020 |
Why?
|
Maternal-Fetal Exchange | 1 | 1990 | 456 | 0.020 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2005 | 1320 | 0.020 |
Why?
|
Chi-Square Distribution | 2 | 2007 | 3503 | 0.020 |
Why?
|
Aspartate Aminotransferases | 2 | 2006 | 418 | 0.020 |
Why?
|
Renin | 1 | 2010 | 642 | 0.020 |
Why?
|
Apoproteins | 1 | 1987 | 44 | 0.020 |
Why?
|
Nitriles | 1 | 2013 | 953 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 1994 | 788 | 0.020 |
Why?
|
Antigens, CD | 3 | 2004 | 4026 | 0.020 |
Why?
|
Centrifugation, Density Gradient | 1 | 1987 | 313 | 0.020 |
Why?
|
Temperature | 1 | 1994 | 2202 | 0.020 |
Why?
|
Serum Albumin | 2 | 1988 | 675 | 0.020 |
Why?
|
Asthma | 2 | 2000 | 6010 | 0.020 |
Why?
|
Potassium | 2 | 1995 | 1336 | 0.020 |
Why?
|
Apolipoprotein C-II | 1 | 1986 | 11 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2001 | 13691 | 0.020 |
Why?
|
Bronchodilator Agents | 1 | 1990 | 502 | 0.020 |
Why?
|
Graft Rejection | 1 | 2000 | 4398 | 0.020 |
Why?
|
Alanine Transaminase | 2 | 2006 | 593 | 0.020 |
Why?
|
Peptidoglycan | 1 | 1989 | 246 | 0.020 |
Why?
|
Models, Statistical | 2 | 2007 | 5100 | 0.020 |
Why?
|
Kinetics | 1 | 1995 | 6476 | 0.020 |
Why?
|
Heart Transplantation | 1 | 2000 | 3113 | 0.020 |
Why?
|
Arthritis, Experimental | 1 | 1989 | 291 | 0.020 |
Why?
|
Apolipoprotein A-II | 1 | 1986 | 39 | 0.020 |
Why?
|
Massachusetts | 3 | 2007 | 8660 | 0.020 |
Why?
|
Beverages | 1 | 2012 | 820 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2007 | 6170 | 0.020 |
Why?
|
Nitric Oxide | 1 | 2015 | 2132 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2010 | 676 | 0.020 |
Why?
|
Hippurates | 1 | 2006 | 16 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2009 | 610 | 0.020 |
Why?
|
alpha-Macroglobulins | 1 | 2006 | 64 | 0.020 |
Why?
|
Maternal Age | 1 | 2009 | 802 | 0.020 |
Why?
|
Health Care Reform | 1 | 2015 | 1261 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2001 | 2274 | 0.020 |
Why?
|
Forecasting | 2 | 2010 | 2950 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2008 | 710 | 0.020 |
Why?
|
Taurine | 1 | 2006 | 94 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 3000 | 0.020 |
Why?
|
Dextrans | 1 | 1987 | 595 | 0.020 |
Why?
|
Methionine | 1 | 2007 | 590 | 0.020 |
Why?
|
Kidney Diseases | 2 | 2004 | 2146 | 0.020 |
Why?
|
Monitoring, Physiologic | 2 | 2004 | 1738 | 0.020 |
Why?
|
Demyelinating Diseases | 1 | 1987 | 354 | 0.020 |
Why?
|
Up-Regulation | 2 | 2007 | 4221 | 0.020 |
Why?
|
Survival | 1 | 2005 | 163 | 0.020 |
Why?
|
Plasma | 1 | 2008 | 575 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2004 | 5691 | 0.020 |
Why?
|
Albumins | 1 | 1987 | 568 | 0.020 |
Why?
|
Hand Strength | 1 | 2007 | 448 | 0.020 |
Why?
|
Chemokine CCL2 | 1 | 2007 | 620 | 0.020 |
Why?
|
Ventricular Remodeling | 1 | 2012 | 1225 | 0.020 |
Why?
|
Cervix Uteri | 1 | 2008 | 590 | 0.020 |
Why?
|
Glycine | 1 | 2007 | 670 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2009 | 1537 | 0.010 |
Why?
|
Mice | 3 | 2008 | 81154 | 0.010 |
Why?
|
Bone Diseases, Metabolic | 1 | 2008 | 417 | 0.010 |
Why?
|
Body Weight | 3 | 2003 | 4670 | 0.010 |
Why?
|
Hemoglobins, Abnormal | 1 | 1984 | 119 | 0.010 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2005 | 164 | 0.010 |
Why?
|
Hemochromatosis | 1 | 2005 | 184 | 0.010 |
Why?
|
Ultrasonography, Interventional | 1 | 2012 | 1486 | 0.010 |
Why?
|
Blood Preservation | 1 | 2004 | 177 | 0.010 |
Why?
|
Cell Line | 2 | 1996 | 15993 | 0.010 |
Why?
|
Ice | 1 | 2004 | 104 | 0.010 |
Why?
|
Arthritis | 1 | 1989 | 661 | 0.010 |
Why?
|
Depression | 1 | 2023 | 7760 | 0.010 |
Why?
|
Hemodynamics | 1 | 1994 | 4197 | 0.010 |
Why?
|
Temperance | 1 | 2003 | 89 | 0.010 |
Why?
|
Neoplasm Staging | 2 | 2010 | 11036 | 0.010 |
Why?
|
Osteoblasts | 1 | 1989 | 1164 | 0.010 |
Why?
|
Prothrombin | 1 | 2003 | 185 | 0.010 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1998 | 2428 | 0.010 |
Why?
|
Plasminogen Activators | 1 | 2003 | 209 | 0.010 |
Why?
|
International Cooperation | 2 | 2000 | 1419 | 0.010 |
Why?
|
Lysine | 1 | 2007 | 1007 | 0.010 |
Why?
|
Xanthophylls | 1 | 2002 | 96 | 0.010 |
Why?
|
Endothelium | 1 | 2005 | 777 | 0.010 |
Why?
|
Chelating Agents | 1 | 2004 | 379 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2013 | 1787 | 0.010 |
Why?
|
Thromboembolism | 1 | 2009 | 987 | 0.010 |
Why?
|
Stress, Mechanical | 1 | 2008 | 1684 | 0.010 |
Why?
|
Liver | 3 | 2005 | 7479 | 0.010 |
Why?
|
Rural Population | 1 | 1993 | 2207 | 0.010 |
Why?
|
Glucocorticoids | 1 | 1992 | 2107 | 0.010 |
Why?
|
Patient Compliance | 1 | 1993 | 2683 | 0.010 |
Why?
|
Lutein | 1 | 2002 | 125 | 0.010 |
Why?
|
Respiration Disorders | 1 | 2005 | 371 | 0.010 |
Why?
|
Endpoint Determination | 1 | 2005 | 601 | 0.010 |
Why?
|
Coronary Restenosis | 1 | 2005 | 424 | 0.010 |
Why?
|
Diet, Fat-Restricted | 1 | 2004 | 320 | 0.010 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2003 | 179 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2011 | 2703 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1987 | 685 | 0.010 |
Why?
|
Fatty Acids, Omega-6 | 1 | 2003 | 227 | 0.010 |
Why?
|
Siblings | 1 | 2006 | 853 | 0.010 |
Why?
|
Exons | 1 | 2007 | 2438 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 2 | 2006 | 8300 | 0.010 |
Why?
|
Eicosanoids | 1 | 2003 | 279 | 0.010 |
Why?
|
Fishes | 1 | 2004 | 569 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2003 | 15281 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1995 | 19232 | 0.010 |
Why?
|
Blood Coagulation Factors | 1 | 2003 | 355 | 0.010 |
Why?
|
Antifibrinolytic Agents | 1 | 2003 | 254 | 0.010 |
Why?
|
Autoantibodies | 1 | 2009 | 2037 | 0.010 |
Why?
|
Anticarcinogenic Agents | 1 | 2002 | 253 | 0.010 |
Why?
|
Geriatric Assessment | 1 | 2008 | 1372 | 0.010 |
Why?
|
Mutation | 1 | 2005 | 29777 | 0.010 |
Why?
|
Length of Stay | 2 | 2008 | 6311 | 0.010 |
Why?
|
Health Personnel | 2 | 2005 | 3217 | 0.010 |
Why?
|
False Positive Reactions | 2 | 1998 | 980 | 0.010 |
Why?
|
Food Analysis | 1 | 2001 | 104 | 0.010 |
Why?
|
Chemokines | 1 | 2004 | 968 | 0.010 |
Why?
|
Ankle | 1 | 2003 | 327 | 0.010 |
Why?
|
Heparin | 1 | 1987 | 1637 | 0.010 |
Why?
|
Systole | 1 | 2002 | 958 | 0.010 |
Why?
|
Birth Weight | 1 | 2008 | 2069 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2005 | 1364 | 0.010 |
Why?
|
Dietary Proteins | 1 | 2005 | 962 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2007 | 2538 | 0.010 |
Why?
|
Rest | 1 | 2004 | 901 | 0.010 |
Why?
|
Haplotypes | 1 | 2006 | 2779 | 0.010 |
Why?
|
Retreatment | 1 | 2001 | 609 | 0.010 |
Why?
|
Cystatin C | 1 | 2001 | 249 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 971 | 0.010 |
Why?
|
Sex Distribution | 1 | 2005 | 2298 | 0.010 |
Why?
|
Cesarean Section | 1 | 2008 | 1365 | 0.010 |
Why?
|
Lung | 1 | 1998 | 9858 | 0.010 |
Why?
|
Software | 1 | 2014 | 4440 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2004 | 12954 | 0.010 |
Why?
|
Carotenoids | 1 | 2002 | 623 | 0.010 |
Why?
|
Anesthesia, Epidural | 1 | 2001 | 228 | 0.010 |
Why?
|
Oxygen | 2 | 1991 | 4189 | 0.010 |
Why?
|
Heterozygote | 1 | 2006 | 2803 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2006 | 11360 | 0.010 |
Why?
|
Nonlinear Dynamics | 1 | 2001 | 501 | 0.010 |
Why?
|
Anticoagulants | 1 | 1994 | 4599 | 0.010 |
Why?
|
Indoles | 1 | 2007 | 1841 | 0.010 |
Why?
|
Ultrasonography | 2 | 2004 | 5986 | 0.010 |
Why?
|
Diarrhea | 1 | 2005 | 1348 | 0.010 |
Why?
|
Heart Rate | 2 | 2004 | 4091 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 1995 | 9272 | 0.010 |
Why?
|
Mast Cells | 1 | 2006 | 1544 | 0.010 |
Why?
|
TRPP Cation Channels | 1 | 1999 | 176 | 0.010 |
Why?
|
Coronary Circulation | 1 | 2004 | 1572 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 2001 | 1151 | 0.010 |
Why?
|
Food | 1 | 2003 | 771 | 0.010 |
Why?
|
Antibodies | 1 | 2006 | 2459 | 0.010 |
Why?
|
Models, Biological | 2 | 2007 | 9582 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2019 | 77410 | 0.010 |
Why?
|
Myocardial Revascularization | 1 | 2001 | 841 | 0.010 |
Why?
|
Models, Cardiovascular | 1 | 2003 | 996 | 0.010 |
Why?
|
Coronary Artery Bypass | 1 | 2007 | 2288 | 0.010 |
Why?
|
Blood Sedimentation | 1 | 1998 | 231 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 1998 | 429 | 0.010 |
Why?
|
Apnea | 1 | 1998 | 195 | 0.010 |
Why?
|
Pericardium | 1 | 2001 | 667 | 0.010 |
Why?
|
Papio | 1 | 1998 | 656 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2008 | 3608 | 0.010 |
Why?
|
Islets of Langerhans | 1 | 2003 | 1350 | 0.010 |
Why?
|
Hyperoxia | 1 | 1998 | 262 | 0.010 |
Why?
|
Homeostasis | 1 | 2007 | 3337 | 0.010 |
Why?
|
Walking | 1 | 2003 | 1182 | 0.010 |
Why?
|
Demography | 1 | 2000 | 1653 | 0.010 |
Why?
|
Causality | 1 | 2002 | 1275 | 0.010 |
Why?
|
Treatment Failure | 1 | 2001 | 2617 | 0.010 |
Why?
|
Nociceptors | 1 | 1998 | 432 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2005 | 2794 | 0.010 |
Why?
|
Progesterone | 1 | 1999 | 773 | 0.010 |
Why?
|
Acute Kidney Injury | 1 | 1987 | 1968 | 0.010 |
Why?
|
Succimer | 1 | 1994 | 31 | 0.010 |
Why?
|
Technetium Tc 99m Dimercaptosuccinic Acid | 1 | 1994 | 79 | 0.010 |
Why?
|
Clinical Enzyme Tests | 1 | 1994 | 115 | 0.010 |
Why?
|
Heart Arrest | 1 | 2004 | 1470 | 0.010 |
Why?
|
Anesthesia, General | 1 | 2001 | 1171 | 0.010 |
Why?
|
Organotechnetium Compounds | 1 | 1994 | 137 | 0.010 |
Why?
|
Disease Models, Animal | 3 | 1998 | 18027 | 0.010 |
Why?
|
Anorexia | 1 | 1994 | 161 | 0.010 |
Why?
|
Data Collection | 1 | 2003 | 3339 | 0.010 |
Why?
|
Child Development | 1 | 2005 | 2212 | 0.010 |
Why?
|
Aortic Aneurysm | 1 | 1998 | 644 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2003 | 6620 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2006 | 3482 | 0.010 |
Why?
|
Drug Tolerance | 1 | 1994 | 376 | 0.010 |
Why?
|
Neurosecretory Systems | 1 | 1994 | 231 | 0.010 |
Why?
|
Epilepsy, Generalized | 1 | 1994 | 174 | 0.010 |
Why?
|
Charcoal | 1 | 1992 | 62 | 0.010 |
Why?
|
Heart Ventricles | 1 | 2004 | 3817 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2004 | 8637 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2001 | 1789 | 0.010 |
Why?
|
Prednisolone | 1 | 1992 | 334 | 0.010 |
Why?
|
Primary Health Care | 1 | 2007 | 4556 | 0.010 |
Why?
|
Psychophysiology | 1 | 1991 | 135 | 0.010 |
Why?
|
Theophylline | 1 | 1990 | 132 | 0.010 |
Why?
|
Physical Education and Training | 1 | 1991 | 106 | 0.010 |
Why?
|
Ammonia | 1 | 1991 | 239 | 0.010 |
Why?
|
Heart Function Tests | 1 | 1991 | 328 | 0.010 |
Why?
|
Chronic Disease | 2 | 1999 | 9139 | 0.010 |
Why?
|
Patient Selection | 1 | 2002 | 4210 | 0.010 |
Why?
|
Erythrocyte Aging | 1 | 1989 | 52 | 0.010 |
Why?
|
Safety | 1 | 1994 | 1184 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2008 | 12259 | 0.010 |
Why?
|
Apoptosis | 1 | 2006 | 9718 | 0.010 |
Why?
|
Flame Ionization | 1 | 1988 | 2 | 0.010 |
Why?
|
Verbal Behavior | 1 | 1991 | 340 | 0.010 |
Why?
|
Acid Phosphatase | 1 | 1989 | 142 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1995 | 3128 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1990 | 647 | 0.010 |
Why?
|
Drug Combinations | 1 | 1994 | 1958 | 0.010 |
Why?
|
gamma-Glutamyltransferase | 1 | 1989 | 134 | 0.010 |
Why?
|
Estrogen Antagonists | 1 | 1989 | 151 | 0.010 |
Why?
|
Cytosol | 1 | 1992 | 901 | 0.010 |
Why?
|
Imidazoles | 1 | 1995 | 1206 | 0.010 |
Why?
|
Aerosols | 1 | 1990 | 623 | 0.000 |
Why?
|
L-Lactate Dehydrogenase | 1 | 1989 | 424 | 0.000 |
Why?
|
Wallerian Degeneration | 1 | 1987 | 69 | 0.000 |
Why?
|
Rats, Inbred Lew | 1 | 1989 | 1162 | 0.000 |
Why?
|
Phenotype | 1 | 2004 | 16361 | 0.000 |
Why?
|
Macromolecular Substances | 1 | 1989 | 1454 | 0.000 |
Why?
|
Fever | 1 | 1994 | 1616 | 0.000 |
Why?
|
Respiratory Function Tests | 1 | 1990 | 1615 | 0.000 |
Why?
|
Alkaline Phosphatase | 1 | 1989 | 866 | 0.000 |
Why?
|
Electrolytes | 1 | 1986 | 282 | 0.000 |
Why?
|
Rheumatic Diseases | 1 | 1992 | 593 | 0.000 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 1994 | 1004 | 0.000 |
Why?
|
Amino Acids | 1 | 1991 | 1733 | 0.000 |
Why?
|
Oxygen Consumption | 1 | 1991 | 1869 | 0.000 |
Why?
|
Mice, Transgenic | 1 | 1995 | 9731 | 0.000 |
Why?
|
Prostatic Hyperplasia | 1 | 1986 | 518 | 0.000 |
Why?
|
Cardiac Surgical Procedures | 1 | 1997 | 3537 | 0.000 |
Why?
|
Receptors, Estrogen | 1 | 1989 | 2190 | 0.000 |
Why?
|
Cell Differentiation | 1 | 1989 | 11478 | 0.000 |
Why?
|